OBJECTIVES: Self-administered injection treatment can be challenging for MS patients. In this market survey, we investigated patients’ evaluation of an electronic autoinjector A for interferon-beta-1b, an electronic autoinjector B for interferon-beta-1a and a mechanical autoinjector C for interferon-beta-1b in supporting self-administration. METHODS:  Face-to-face interviews with 100 MS patients in 5 German cities were organized through an independent external market research company. Participants currently either used the autoinjector A (N=46), B (N=41) or C (N=13). All patients were asked 22 questions in the same order. Questions could be answered openly, by marking or via a rating scale (1-10, with 10 as best rating). First, participants designated their autoinjector currently in use, watched an instruction video and answered questions about their own device. Second, patients were asked about their view of an ideal autoinjector. Third, they watched instruction videos for the two devices not in use with the opportunity to dummy inject into a pillow. Finally, patients were asked to compare the devices. RESULTS:  77% of the autoinjector A users indicated high levels of satisfaction (8-10 points on rating scale) with their device, compared to 66% of B and 54% of C users. With respect to their own devices most patients suggested improvements by making the device smaller and enhancing handling. After testing all devices, evaluation of the autoinjectors by the non-users led to highest valuation of the autoinjector A regarding simple handling, start/stop signaling, adjustment of injection speed/depth and reminder function. Finally, patients were asked which injection device they preferred provided their own medication was suitable: 56% chose the autoinjector A, 36% B, 6% C and 2% did not answer. CONCLUSIONS:  In our survey, most MS patients preferred the autoinjector A over B and C. Thus, for many MS patients the autoinjector A may best meet their needs and may help contribute to medication adherence.